Our investigational oncology therapies are designed to address treatment-resistant cancer mutations.
Working to deliver best-in-class pan-variant Tyrosine Kinase Inhibitors (TKIs) to cancer patients.
We are developing a pipeline of TKIs designed to inhibit all major cancer causing and drug resistance mutations in clinically significant protein kinases.
View our latest news.
May 12, 2022